Close Menu

mergers & acquisitions

BD paid $275 million for the privately held molecular diagnostics firm. It will integrate its GeneOhm assays with a new platform based on HandyLab's instrument.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

Qiagen’s goal is to enable its customers to take an assay in a very early stage of discovery and validation and, “without transitioning platforms — to seamlessly move that into a companion diagnostic candidate if they so wish."

The $1.1 billion deal for the MDS Analytical Technologies business is under antitrust review.

Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.

The Belgian life sciences company sees the acquisition as bringing together the firm's respective genomics and proteomics capabilities and their European and US presences.

BD plans to place its GeneOhm assays on HandyLab's Jaguar system.

MDS' shareholders voted in favor of the deal at a special meeting on Tuesday.

OriGene gains products for DNA and RNA purification and multiplex assays for genotyping, microRNA profiling, and transcription factor activity analysis.

BGIP sells a range of bioscience products that are "tailored" to the Indian market, said the German firm.


The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.